$5.43 Million in Sales Expected for Adaptimmune Therapeutics PLC (ADAP) This Quarter

Wall Street brokerages expect Adaptimmune Therapeutics PLC (NASDAQ:ADAP) to report $5.43 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Adaptimmune Therapeutics PLC’s earnings. The lowest sales estimate is $3.00 million and the highest is $7.40 million. Adaptimmune Therapeutics PLC reported sales of $330,000.00 during the same quarter last year, which indicates a positive year over year growth rate of 1,545.5%. The business is expected to announce its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Adaptimmune Therapeutics PLC will report full year sales of $5.43 million for the current fiscal year, with estimates ranging from $11.90 million to $25.00 million. For the next fiscal year, analysts forecast that the business will report sales of $21.19 million per share, with estimates ranging from $12.00 million to $30.00 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that cover Adaptimmune Therapeutics PLC.

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last posted its earnings results on Wednesday, May 10th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by $0.06. The company had revenue of $2.86 million for the quarter, compared to the consensus estimate of $5.07 million. Adaptimmune Therapeutics PLC had a negative net margin of 550.22% and a negative return on equity of 41.40%.

A number of equities research analysts have recently weighed in on ADAP shares. Cowen and Company restated a “buy” rating on shares of Adaptimmune Therapeutics PLC in a research note on Tuesday, June 6th. Zacks Investment Research upgraded Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a research note on Friday, March 10th. Finally, Wells Fargo & Co started coverage on Adaptimmune Therapeutics PLC in a research note on Friday, March 17th. They set a “market perform” rating on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. Adaptimmune Therapeutics PLC presently has a consensus rating of “Hold” and an average price target of $11.83.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/2655638/5-43-million-in-sales-expected-for-adaptimmune-therapeutics-plc-adap-this-quarter.html.

Adaptimmune Therapeutics PLC (NASDAQ ADAP) traded up 2.86% during trading on Friday, reaching $4.68. 72,980 shares of the company’s stock traded hands. The firm’s market cap is $437.56 million. Adaptimmune Therapeutics PLC has a one year low of $3.76 and a one year high of $9.59. The company has a 50 day moving average of $5.13 and a 200 day moving average of $4.70.

In other news, major shareholder Enterprise Associates 14 New bought 12,870,000 shares of the company’s stock in a transaction that occurred on Monday, March 27th. The shares were purchased at an average price of $0.70 per share, for a total transaction of $9,009,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Orbimed Advisors Llc bought 1,190,476 shares of the company’s stock in a transaction that occurred on Monday, March 27th. The stock was purchased at an average price of $4.20 per share, for a total transaction of $4,999,999.20. The disclosure for this purchase can be found here.

A number of large investors have recently modified their holdings of ADAP. Raymond James Financial Services Advisors Inc. purchased a new stake in shares of Adaptimmune Therapeutics PLC during the first quarter worth approximately $120,000. KCG Holdings Inc. purchased a new stake in shares of Adaptimmune Therapeutics PLC during the first quarter worth approximately $133,000. Monashee Investment Management LLC purchased a new stake in shares of Adaptimmune Therapeutics PLC during the first quarter worth approximately $138,000. Paloma Partners Management Co purchased a new stake in shares of Adaptimmune Therapeutics PLC during the first quarter worth approximately $165,000. Finally, Creative Planning raised its stake in shares of Adaptimmune Therapeutics PLC by 32.8% in the first quarter. Creative Planning now owns 40,500 shares of the biotechnology company’s stock worth $223,000 after buying an additional 10,000 shares in the last quarter. Hedge funds and other institutional investors own 56.15% of the company’s stock.

About Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:ADAP”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Get a free copy of the Zacks research report on Adaptimmune Therapeutics PLC (ADAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.